Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	57.6	56.81	70.17	31.16
Short-Term Investments	227.78	248.48	77.31	-
Cash & Short-Term Investments	285.38	305.28	147.48	31.16
Cash Growth	47.68%	107.00%	373.31%	-
Prepaid Expenses	0.1	0.3	1.5	0.11
Restricted Cash	0.11	0.11	0.09	-
Other Current Assets	5.38	4.12	1.81	-
Total Current Assets	290.97	309.8	150.87	31.27
Property, Plant & Equipment	10.87	4.97	4	0.34
Long-Term Deferred Charges	-	-	0.3	-
Other Long-Term Assets	0.21	0.16	0.25	-
Total Assets	302.05	314.93	155.42	31.6
Accounts Payable	2.14	1.95	2.5	1.45
Accrued Expenses	6.24	6.08	5.63	0.21
Current Portion of Leases	1.01	0.74	0.67	-
Total Current Liabilities	9.38	8.77	8.8	1.66
Long-Term Debt	-	-	4.2	10.44
Long-Term Leases	6.83	0.74	1.48	-
Total Liabilities	16.22	9.51	14.48	12.1
Common Stock	0.04	0.04	0	0.03
Additional Paid-In Capital	433.7	429.66	19.8	0.56
Retained Earnings	-147.81	-123.75	-45.44	-10.65
Comprehensive Income & Other	-0.1	-0.52	0	-
Total Common Equity	285.84	305.43	-25.63	-10.06
Shareholders' Equity	285.84	305.43	140.94	19.51
Total Liabilities & Equity	302.05	314.93	155.42	31.6
Total Debt	7.84	1.48	6.35	10.44
Net Cash (Debt)	277.54	303.8	141.13	20.72
Net Cash Growth	45.11%	115.26%	581.01%	-
Net Cash Per Share	9.56	14.65	93.73	26.66
Filing Date Shares Outstanding	36.5	36.5	4.17	0.78
Total Common Shares Outstanding	36.5	36.58	4.17	0.78
Working Capital	281.59	301.04	142.07	29.61
Book Value Per Share	7.83	8.35	-6.15	-12.95
Tangible Book Value	285.84	305.43	-25.63	-10.06
Tangible Book Value Per Share	7.83	8.35	-6.15	-12.95
Machinery	4.33	3.78	1.76	0.3
Construction In Progress	-	0.43	0.03	0.06
Leasehold Improvements	0.28	0.28	0.26	-

Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q